" class="no-js "lang="en-US"> Enrico Bastianelli - Medtech Alert
Friday, April 25, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Enrico Bastianelli

Enrico Bastianelli

About Enrico Bastianelli

Enrico Bastianelli is the founder of TheraVet. Medical Doctor by training and holder of an MBA, Enrico Bastianelli acquired his business experience at McKinsey & Co. After creating several biotech companies, he founded and led Bone Therapeutics (a human bone cell therapy company) for 10 years. During this period, he took up many challenges such as the company’s IPO (2015). He has 20 years of experience in biotech and medtech management.

Related Story

Industry News

 TheraVet Optimizes its Commercial Strategy in France with a New Distribution Agreement with Elvetis | PTF

TheraVet Optimizes its Commercial Strategy in France with a New Distribution Agreement with Elvetis

December 12 2022

TheraVet, a pioneering biotechnology company in the treatment of bone and joint diseases in pets, […]

Diseases

 TheraVet Signs an Important Distribution Agreement With the Orthopaedics & Surgical Instrumentation Distributor

TheraVet Signs an Important Distribution Agreement With the Orthopaedics & Surgical Instrumentation Distributor, Veterinary Instrumentation

May 10 2022

TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases […]